~" There is little information as to the optimal use of mannitol. To determine the dose-response relationship, the osmotic gradient required, and the time course of intracranial pressure (ICP) reduction produced by mannitol, eight patients with acute head injury were studied in whom ICP was monitored with a ventriculostomy and found to be elevated. Ventilation was controlled to a pCO2 of 25 4-3 mm Hg and all were paralyzed with Pavulon. None had received barbiturates. Before mannitol admifiistration the intracranial volume-pressure response was determined. Mannitol was administered as a bolus of 0.25 gm/kg, 0.5 gm/kg, and in six patients, 1 gm/kg, separated by at least 8 hours.
O SMOTIC diuretics have a major role in the reduction of intracranial hypertension in neurosurgical patients. However, there is little documentation of mannitol dose requirements. Current dose schedules suggest 0.5 to 1.5 gm/kg. These recommendations are based upon extrapolations from the dose established for urea 8,5 and from studies in patients, many of whom had little or no intracranial hypertension. In patients requiring many repeated administrations of mannitol, hyperosmolar states associated with acute renal dysfunction can develop. Continuously high serum levels may also enhance mannitol penetration into damaged brain? '8 For these reasons we embarked upon a study to determine the minimum effective dose of mannitol in patients with acute closed head injuries complicated by severe intracranial hypertension (intracranial pressure > 30 mm/Hg).
Clinical Material and Methods
Eight patients with acute severe closed head injuries (no response to verbal stimuli on admission) who had ventriculostomies placed as part of their routine management were studied. Table 1 summarizes their clinical status, the results of the computerized axial tomographic (CT) scans, which were carried out in all patients, the time from injury to the mannitol studies, and the ultimate outcome in these patients. All had intracranial hypertension (mean 44.4 + 5.1 mm Hg) despite controlled ventilation using Pavulon (pancuronium bromide) to achieve a pCO2 of 25 4-3 mm Hg and high-dose dexamethasone (20 mg every 6 hours) therapy. None had received barbiturates. Three doses, 0.25 gm/kg, 0.5 gm/kg, and 1.0 gm/kg, were chosen for study. For each patient the initial experimental mannitol dose was randomly assigned, but no patient received the same dose twice. At least 8 hours separated the doses, and serum osmolalities had returned to baseline for 3 hours in all instances. *No differences (p > 0.05) existed among the required three dose ranges studied in the intracranial pressures (ICP's) or time required to achieve the lowest ICP. VPR = volume-pressure response.
Results
The results are summarized in Tables 2 and  3 . As noted in Table 2 , there was no significant difference in any of the ICP values, in the VPR, or in the time required to achieve the maximum reduction in ICP. Although a significantly increased osmotic gradient was present in those patients receiving 0.5 gm/kg (p < 0.02) and 1 gm/kg (p < 0.01) compared to the low-dose group (Table 3) , there was no difference in the magnitude of reduction in ICP following mannitol administration. At 5 hours there was a nonstatistically significant trend toward a lower ICP in patients receiving the higher mannitol doses.
In three patients given 1 gm/kg, a rise in ICP associated with a rise in SAP of less than l0 mm Hg was observed. This rise occurred within the first 5 minutes of mannitol administration and the ICP increased from 56 to 67 mm Hg in one, from 41 to 46 mm Hg in another, and from 43 to 52 mm Hg in the third. Clinically these increases did not appear to be significant, and they were transient.
Two patients required CSF venting between doses, but the VPR at the time of the next mannitol administration was not significantly different.
Discussion
The present study demonstrates that doses of mannitol much lower than those previously recommended for the control of intracranial hypertension are effective in reducing ICP. The smaller doses are associated with smaller increase in serum osmolality and, therefore, permit more frequent administration if chronic mannitol therapy is required. Although the osmotic gradient was abolished more quickly when the patient was given lowdose mannitol, the relative efficacy of the smaller dose offers a major advantage in avoiding the problem of severe hyperosmolar states and the problem that is perhaps not only theoretical of the extravasation of mannitol into the brain when frequent large doses are given.
The VPR in this group of patients was quite high, indicating that brain compliance had been reduced to a point where relatively small increases in intracranial volume yielded large rises in ICP. One might expect that smaller doses of mannitol would be effective under these particular circumstances since a less marked reduction in intracranial volume would be required than if the VPR and the ICP were both lower. However, in patients with relatively mild intracranial hyper- In the present group of patients, acute rises in ICP associated with the administration of 1 gm/kg of mannitol were not clinically significant. However, under less controlled circumstances such an increase is potentially catastrophic and is avoidable with smaller doses of mannitol.
Despite extremely high ICP's in many of the patients studied, 1 gm/kg versus a smaller dose did not result in a significantly greater reduction in ICP in any of the patients. Our study demonstrates that osmotic gradients of 10 mOsm yield a satisfactory reduction in ICP and this reduction will persist for 3 to 4 hours. Severe dehydration can also be avoided in most patients when a low-dose regimen is used. Our results, therefore, confirm in a more controlled fashion the report of Kfihner, et .al., 1 who also found that much smaller doses than those previously recommended a,5 are effective in the treatment of intracranial hypertension.
